Prostate Cancer Therapeutics Market Research Report, Share, and Forecast to 2025Posted by rekha on October 11th, 2019 The global prostate cancer therapeutics market accounted for US$ 11.4 Bn in 2018 and burgeoning over the forthcoming years. Some of the key factors propelling the market growth are various market players investing in the field of research for developing therapeutic products for treatment of tumors, growing incidences of glandular cancer,rising demand for non-invasive therapies and development of innovative technologies in screening & diagnostic tests. However, high cost of tissue biopsy and unfavorable reimbursement of treatment cost are hindering the growth of the market. Global prostate cancer therapeutics market segmented on the basis of drug class, route of administration, distribution channel, and region. For request sample: https://www.precisionbusinessinsights.com/request-sample?product_id=15737 Chemotherapeutic Agents Dominate the Global Prostate Cancer Therapeutics Market Based on drug class, global prostate cancer therapeutics market segmented into immune system modulators, hormones, chemotherapeutic agents and others. Chemotherapeutic agents segment held considerable market growth during estimated period. Chemotherapy is the use of any one or combination of cancer-fighting drugs. It is prescribed in cases of recurrent or advanced prostate cancer. Chemotherapy is given in cycles of treatment followed by a recovery period. The entire treatment generally lasts three to six months, depending on the type of chemotherapy medications given.Chemotherapy drugs are given intravenously (directly into the vein) or by mouth. Once the drugs are absorbed, they enter the bloodstream and travel to virtually all parts of the body to reach cancer cells that may have spread beyond the prostate. Asia Pacific Leads the Global Prostate Cancer Therapeutics market PBI’s global prostate cancer therapeutics market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis.This region is one of the key markets for prostate cancer therapeutics. The region has witnessed considerable growth in this market due to several governments in this country building awareness programs with the help of online portals about screening & diagnosis tests, growing awareness of disease, rising investments by market players in developing immunotherapies and targeted therapies. Europe and North America are likely to witness steady growth in this market owing to advanced healthcare infrastructure facilities and huge number of patients affected with this disease. Strategic Acquisitions are the Key Strategies Adopted by Market Players Global prostate cancer therapeutics market further reveals that the key player’s increasingly adopting strategies such as strategic acquisitions and launch of new products to improve market revenue share and gaining significant geographic presence across the region. For Instance, in 2018, Telix acquired Atlab for prostate cancer program. This acquisition gives Telix a significant edge in the combination use of PSMA-targeting therapeutics with androgen-targeting drugs such as Zytiga®2 and Xtandi®3” and bring a considerable depth of knowledge around antibody-based on PSMA therapeutics. Key player’s profiles in the report are Endo Pharmaceuticals Inc. (USA), Dendreon Pharmaceuticals LLC (USA), Debiopharm Group (Switzerland), Bristol-Myers Squibb Company (USA), Bayer AG (Germany), AstraZeneca Plc. (UK), Astellas Pharma, Inc. (Japan), Amgen, Inc. (USA), Allergan plc (Ireland) and AbbVie, Inc. (USA). Precision Business Insights (PBI) in its report titled “Global Prostate Cancer Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market. Detailed Segmentation
By Drug Class o Immune System Modulators o Hormones o Chemotherapeutic agents o Others By Route of Administration o Parenteral o Oral o Others By Distribution Channel o Hospital Pharmacy o Retail Pharmacy o Others By Geography o North America
o Europe
o Asia-Pacific
o Latin America
o Middle East and Africa (MEA)
For more information: https://www.precisionbusinessinsights.com/market-reports/global-prostate-cancer-therapeutics-market/ Like it? Share it! More by this author |